AU2001275537A1 - N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith - Google Patents

N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith

Info

Publication number
AU2001275537A1
AU2001275537A1 AU2001275537A AU7553701A AU2001275537A1 AU 2001275537 A1 AU2001275537 A1 AU 2001275537A1 AU 2001275537 A AU2001275537 A AU 2001275537A AU 7553701 A AU7553701 A AU 7553701A AU 2001275537 A1 AU2001275537 A1 AU 2001275537A1
Authority
AU
Australia
Prior art keywords
diphenylmethoxy
phenyl
ethyl
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275537A
Inventor
Aloke K. Dutta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2001275537A1 publication Critical patent/AU2001275537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
AU2001275537A 2000-06-20 2001-06-14 N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith Abandoned AU2001275537A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21292100P 2000-06-20 2000-06-20
US60212921 2000-06-20
PCT/US2001/040964 WO2001098266A2 (en) 2000-06-20 2001-06-14 N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith

Publications (1)

Publication Number Publication Date
AU2001275537A1 true AU2001275537A1 (en) 2002-01-02

Family

ID=22792949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275537A Abandoned AU2001275537A1 (en) 2000-06-20 2001-06-14 N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith

Country Status (3)

Country Link
US (3) US6995268B2 (en)
AU (1) AU2001275537A1 (en)
WO (1) WO2001098266A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523408A (en) * 2000-02-22 2003-08-05 バイオストリーム インク Imaging agents for diagnosing Parkinson's disease
AU2001275537A1 (en) * 2000-06-20 2002-01-02 Wayne State University N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US20060122263A1 (en) * 2003-03-28 2006-06-08 Dutta Aloke K Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
US7531555B2 (en) 2003-10-01 2009-05-12 University Of Florida Research Foundation, Inc. Compositions and methods for selective inhibition of nicotine acetylcholine receptors
EP1734948B1 (en) 2004-04-16 2014-06-11 Wayne State University Tri-substitued 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
DE602005019182D1 (en) 2004-09-30 2010-03-18 Ibiden Co Ltd hONEYCOMB STRUCTURE
JP5142532B2 (en) * 2004-11-26 2013-02-13 イビデン株式会社 Honeycomb structure
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
JP2009539806A (en) * 2006-06-08 2009-11-19 シュペーデル・エクスペリメンタ・アーゲー 2,5-disubstituted piperidine
WO2009073620A2 (en) * 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP3233799B1 (en) * 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598750B2 (en) 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
ES2086341T3 (en) 1989-09-12 1996-07-01 Hoechst Ag DERIVATIVES OF AMINO ACIDS WITH RENINE INHIBITING PROPERTIES, PROCEDURE FOR THEIR PREPARATION, AGENTS CONTAINING THEM AND THEIR USE.
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
GB9000301D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
JPH09249566A (en) 1996-03-19 1997-09-22 Takeda Chem Ind Ltd Piperidine-containing chemokine receptor antagonist
US6369077B1 (en) 1997-05-08 2002-04-09 Smithkline Beecham Corporation Protease inhibitors
CN100418951C (en) * 1997-11-18 2008-09-17 帝人医药株式会社 Cycloamine derivative and its use as medicine
ES2235883T3 (en) * 1999-05-06 2005-07-16 Neurogen Corporation 4-OXO-QUINOLINO-3-SUBSTITUTED CARBOXAMIDS: GABA CEREBRAL RECEIVERS LIGANDOS.
AU2001275537A1 (en) * 2000-06-20 2002-01-02 Wayne State University N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith

Also Published As

Publication number Publication date
US20030225133A1 (en) 2003-12-04
WO2001098266A2 (en) 2001-12-27
US7595331B2 (en) 2009-09-29
US6995268B2 (en) 2006-02-07
US20050154021A1 (en) 2005-07-14
WO2001098266A3 (en) 2002-04-04
US20100016600A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
AU2001275537A1 (en) N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
IL150813A0 (en) Substituted glutarimides and use thereof il-12 production inhibitors
HUP0101737A3 (en) Methods and compositions for pulmonary and nasal administration of raloxifene
AU2002243230A1 (en) Piperidine/piperazine-type inhibitors of p38 kinase
HU9603237D0 (en) Kristalline hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxydo-3-oxo-2,3-dihydro-benzisothiazo-2-yl)-butyl]-amino-methyl}-chromane
AU2002222172A1 (en) Method of retrieving entities
HK1039114A1 (en) 4-(Aminomethyl)-piperidine benzamides for treatinggastrointestinal disorders.
AU2001244418A1 (en) Method for defining and controlling the overall behavior of a network processor device
IL155041A0 (en) Process for the preparation of n-(substituted phenyl)-3-alkyl-, aryl-and heteroarylsulfonyl-2-hydroxy-2-alkyl-and haloalkylpropanamide compounds
HK1069823A1 (en) Method for separating methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4- dihydro-5-pyrimidine- carboxylate- racemate
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0031145D0 (en) Compounds that effect cd83 expression pharmaceutical compositions comprising said compounds and methods for identifying said compounds
EP1292305A4 (en) METHOD OF DOPAMINE INHIBITION USING i L-THREO /i -METHYLPHENIDATE
WO2002046156A3 (en) 4,4-disubstituted piperidines, and methods of use thereof
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
AU2002220372A1 (en) Method for screening for inhibitors of alzheimer's disease
ITUD20000172A0 (en) DEVICE AND PROCEDURE FOR SANITIZING FOOTWEAR
HUP0303418A3 (en) Inhibitors of papilloma virus
ITBO20000510A0 (en) EQUIPMENT AND METHOD FOR CONSTRUCTION OF TRACHEOSTOMY
ITMI20002189A0 (en) PROCEDURE FOR CONTROLLING ACCESS TO A TELEMATIC NETWORK
AU5531001A (en) Stabilized formulations of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl) benzo(B)thiophene and salts thereof
IL157061A0 (en) Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof
AU4595100A (en) ((e),3(r))-enantiomer of 4-(3-chloro -4-cyanophenyl) -1-(p- methylsulphonyl -phenylsulphonyl) -2-trifluoromethylbut -trans-3-en-ol
HUP0105124A3 (en) 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone and method for its preparation
HU0104099D0 (en) Method for limiting dymics response of audio sygnals